# Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.

> **NCT02697474** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 150 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Euvax B®: Hepatitis B vaccine
- **BIOLOGICAL:** Euvax B®: Hepatitis B vaccine

## Key facts

- **NCT ID:** NCT02697474
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-06
- **Final completion:** 2017-01
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02697474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02697474, "Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02697474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*